| Year |
Citation |
Score |
| 2024 |
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang YV, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, ... ... Hanker AB, et al. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature Communications. 15: 2287. PMID 38480701 DOI: 10.1038/s41467-024-46495-2 |
0.496 |
|
| 2024 |
Marquez-Palencia M, Reza Herrera L, Parida PK, Ghosh S, Kim K, Das NM, Gonzalez-Ericsson PI, Sanders ME, Mobley BC, Diegeler S, Aguilera TA, Peng Y, Lewis CM, Arteaga CL, Hanker AB, et al. AXL/WRNIP1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in HER2+ breast cancer. Cancer Research. PMID 38190717 DOI: 10.1158/0008-5472.CAN-23-1459 |
0.384 |
|
| 2023 |
Xu Y, Wang Z, Sjöström M, Deng S, Wang C, Johnson NA, Gonzalez J, Li X, Metang LA, Tirado CR, Mukherji A, Wainwright G, Yu X, Yang Y, Barnes S, ... ... Hanker A, et al. ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers. Biorxiv : the Preprint Server For Biology. PMID 37961351 DOI: 10.1101/2023.10.24.563645 |
0.378 |
|
| 2023 |
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang Y, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, ... ... Hanker A, et al. Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Research Square. PMID 37502925 DOI: 10.21203/rs.3.rs-2966905/v1 |
0.503 |
|
| 2023 |
Kim BJ, Zheng ZY, Lei JT, Holt MV, Chen A, Peng J, Fandino D, Singh P, Kennedy H, Dou Y, Chica-Parrado MDR, Bikorimana E, Ye D, Wang Y, Hanker AB, et al. Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Research Communications. 3: 1366-1377. PMID 37501682 DOI: 10.1158/2767-9764.CRC-23-0044 |
0.326 |
|
| 2023 |
Marin A, Mamun AA, Patel H, Akamatsu H, Ye D, Sudhan DR, Eli L, Marcelain K, Brown BP, Meiler J, Arteaga CL, Hanker AB. Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer. Cancer Research. PMID 37404061 DOI: 10.1158/0008-5472.CAN-22-3617 |
0.522 |
|
| 2023 |
Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Singareeka Raghavendra A, Yang-Kolodji G, Chu F, Neelapu SS, Marchese A, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Research : Bcr. 25: 62. PMID 37280713 DOI: 10.1186/s13058-023-01665-w |
0.452 |
|
| 2023 |
Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Raghavendra AS, Yang-Kolodji G, Chu F, Neelapu SS, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Research Square. PMID 36824840 DOI: 10.21203/rs.3.rs-2388864/v1 |
0.502 |
|
| 2022 |
Lee KM, Lin CC, Servetto A, Bae J, Kandagatla V, Ye D, Kim GM, Sudhan DR, Mendiratta S, Gonzalez-Ericsson PI, Balko JM, Lee J, Barnes S, Malladi VS, Tabrizi S, ... ... Hanker AB, et al. Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple negative breast cancer. Cancer Immunology Research. PMID 35561311 DOI: 10.1158/2326-6066.CIR-21-0826 |
0.336 |
|
| 2022 |
Parida PK, Marquez-Palencia M, Nair V, Kaushik AK, Kim K, Sudderth J, Quesada-Diaz E, Cajigas A, Vemireddy V, Gonzalez-Ericsson PI, Sanders ME, Mobley BC, Huffman K, Sahoo S, Alluri P, ... ... Hanker AB, et al. Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness. Cell Metabolism. 34: 90-105.e7. PMID 34986341 DOI: 10.1016/j.cmet.2021.12.001 |
0.342 |
|
| 2021 |
Hanker AB, Brown BP, Meiler J, Marín A, Jayanthan HS, Ye D, Lin CC, Akamatsu H, Lee KM, Chatterjee S, Sudhan DR, Servetto A, Brewer MR, Koch JP, Sheehan JH, et al. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell. PMID 34171264 DOI: 10.1016/j.ccell.2021.06.001 |
0.485 |
|
| 2021 |
Servetto A, Kollipara R, Formisano L, Lin CC, Lee KM, Sudhan DR, Gonzalez-Ericsson PI, Chatterjee S, Guerrero-Zotano A, Mendiratta S, Akamatsu H, James N, Bianco R, Hanker AB, Kittler R, et al. Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ER+ breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34011560 DOI: 10.1158/1078-0432.CCR-20-3905 |
0.487 |
|
| 2020 |
Lee KM, Guerrero-Zotano AL, Servetto A, Sudhan DR, Lin CC, Formisano L, Jansen VM, González-Ericsson P, Sanders ME, Stricker TP, Raj G, Dean KM, Fiolka R, Cantley LC, Hanker AB, et al. Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. Nature Communications. 11: 5488. PMID 33127913 DOI: 10.1038/s41467-020-19291-x |
0.549 |
|
| 2020 |
Hanker AB, Sudhan DR, Arteaga CL. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell. 37: 496-513. PMID 32289273 DOI: 10.1016/J.Ccell.2020.03.009 |
0.569 |
|
| 2020 |
Sudhan DR, Guerrero-Zotano A, Won H, Ericsson PG, Servetto A, Huerta-Rosario M, Ye D, Lee KM, Formisano L, Guo Y, Liu Q, Kinch LN, Brewer MR, Dugger T, Koch J, ... ... Hanker AB, et al. Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. Cancer Cell. 37: 258-259. PMID 32049049 DOI: 10.1016/j.ccell.2020.01.010 |
0.39 |
|
| 2020 |
Sudhan DR, Guerrero-Zotano A, Won H, González Ericsson P, Servetto A, Huerta-Rosario M, Ye D, Lee KM, Formisano L, Guo Y, Liu Q, Kinch LN, Red Brewer M, Dugger T, Koch J, ... ... Hanker AB, et al. Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. Cancer Cell. PMID 31978326 DOI: 10.1016/J.Ccell.2019.12.013 |
0.527 |
|
| 2020 |
Servetto A, Kollipara R, Formisano L, Lee K, Sudhan DR, Hanker AB, Chatterjee S, Lin A, Mendiratta S, James N, Kittler R, Arteaga CL. Abstract PD7-04: Fibroblast growth factor receptor 1 associates with promoters genome-wide and regulates gene transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd7-04 |
0.529 |
|
| 2020 |
Lee K, Guerrero-Zotano A, Hanker A, Servetto A, Sudhan D, Formisano L, Jansen V, González-Ericsson P, Sanders M, Stricker T, Cantley L, Arteaga C. Abstract GS6-06: A neoadjuvant trial with letrozole identifies PRR11 in the 17q23 amplicon as a mechanism of resistance to endocrine therapy in ER-positive breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs6-06 |
0.554 |
|
| 2020 |
Hanker AB, Jayanthan HS, Ye D, Lin C, Akamatsu H, Sheehan JH, Koch JP, Sudhan DR, Brewer MR, Servetto A, He J, Miller VA, Lalani AS, Meiler J, Arteaga CL. Abstract GS6-04: Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs6-04 |
0.609 |
|
| 2020 |
Akamatsu H, Mino R, Mettlen M, Ye D, Sudhan DR, Lin A, Marin A, Servetto A, Lee K, Chatterjee S, Schmid SL, Arteaga CL, Hanker AB. Abstract 3675: HER2 missense mutations in breast cancer cells do not alter HER2 internalization or sensitivity to T-DM1 Cancer Research. 80: 3675-3675. DOI: 10.1158/1538-7445.Am2020-3675 |
0.575 |
|
| 2019 |
Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nature Communications. 10: 1373. PMID 30914635 DOI: 10.1038/S41467-019-09068-2 |
0.594 |
|
| 2019 |
Hanker AB, Kaklamani V, Arteaga CL. Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors. Cancer Discovery. PMID 30867161 DOI: 10.1158/2159-8290.Cd-18-1175 |
0.397 |
|
| 2019 |
Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, et al. Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 1434. PMID 30770493 DOI: 10.1158/1078-0432.CCR-18-4267 |
0.521 |
|
| 2019 |
Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL. Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2 Breast Cancer. Cancer Research. 79: 873. PMID 30770368 DOI: 10.1158/0008-5472.CAN-18-4085 |
0.498 |
|
| 2019 |
Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, et al. Correction: An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discovery. 9: 303. PMID 30737217 DOI: 10.1158/2159-8290.Cd-18-1515 |
0.576 |
|
| 2019 |
Hanker A, Koch J, Ye D, Sliwoski G, Sheehan J, Kinch L, Brewer MR, He J, Miller V, Lalani A, Cutler R, Croessmann S, Zabransky D, Meiler J, Arteaga C. Abstract PD3-05: Co-occurring gain-of-function mutations in HER2 and HER3 cooperate to enhance HER2/HER3 binding, HER-dependent signaling, and breast cancer growth Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Pd3-05 |
0.528 |
|
| 2019 |
Servetto A, Formisano L, Kollipara R, Sudhan DR, Lee K, Chatterjee S, Hanker AB, Mendiratta S, Kittler R, Arteaga CL. Abstract 4402: FGFR1 signaling modulates estrogen-independent ER transcriptional activity in ER+/FGFR1-amplified breast cancer cells Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4402 |
0.519 |
|
| 2019 |
Sudhan DR, Hanker AB, Guerrero-Zotano A, Formisano L, Guo Y, Liu Q, Avogadri-Connors F, Cutler RE, Lalani AS, Bryce R, Auerbach A, Arteaga CL. Abstract 1828: Hyperactivation of mTORC1 drives acquired resistance to the pan HER tyrosine kinase inhibitor neratinib in HER2 mutant cancers Cancer Research. 78: 1828-1828. DOI: 10.1158/1538-7445.Am2018-1828 |
0.549 |
|
| 2017 |
Mishra R, Hanker AB, Garrett JT. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget. 8: 114371-114392. PMID 29371993 DOI: 10.18632/Oncotarget.22825 |
0.503 |
|
| 2017 |
Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Gianni L, Koch JP, Tyson DR, Sanchez V, Rexer BN, Sanders M, Zhao Z, Stricker T, Arteaga CL. Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2+ breast cancer. Cancer Research. PMID 28396358 DOI: 10.1158/0008-5472.Can-16-2808 |
0.498 |
|
| 2017 |
Hanker AB, Garrett JG, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford EM, Owns P, Becker J, Groseclose MR, Castellino S, et al. HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28381415 DOI: 10.1158/1078-0432.Ccr-16-2287 |
0.588 |
|
| 2017 |
Hanker AB, Red Brewer M, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, et al. An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discovery. PMID 28274957 DOI: 10.1158/2159-8290.Cd-16-1431 |
0.615 |
|
| 2017 |
Formisano L, Lu Y, Jansen V, Bauer J, Hanker A, Ericsson PG, Lee K, Nixon M, Guerrero-Zotano A, Schwarz L, Sanders M, Sudhan D, Dugger T, Cruz, Behdad A, et al. Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer Cancer Research. 78: 1008-1008. DOI: 10.1158/1538-7445.Sabcs17-Gs6-05 |
0.608 |
|
| 2017 |
Hanker A, Brewer MR, Sheehan J, Koch J, Lanman R, Hyman D, Cutler R, Lalani A, Cross D, Lovly C, Meiler J, Arteaga C. Abstract P3-03-03: An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-03-03 |
0.577 |
|
| 2017 |
Hanker AB. Matching Novel Breast Cancer Mutations With Potential Therapies Oncology Times. 39: 36-37. DOI: 10.1097/01.Cot.0000527369.44911.10 |
0.559 |
|
| 2016 |
Cheng F, Zhao J, Hanker AB, Brewer MR, Arteaga CL, Zhao Z. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer. Breast Cancer Research and Treatment. PMID 27771839 DOI: 10.1007/S10549-016-4011-9 |
0.605 |
|
| 2016 |
Sorace AG, Quarles CC, Whisenant JG, Hanker AB, McIntyre JO, Sanchez VM, Yankeelov TE. Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results. Breast Cancer Research and Treatment. 155: 273-84. PMID 26791520 DOI: 10.1007/S10549-016-3680-8 |
0.445 |
|
| 2016 |
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Weigelt B, Sakr RA, King TA, Chandarlapaty S, Reis-Filho JS, Hanker AB, Arteaga CL, Yeon PS, Michor F, Polyak K. Abstract PR05: The effect of chemotherapy on HER2+ breast cancer heterogeneity measured by STAR-FISH: Detection of PIK3CA mutation and HER2 amplification at single-cell level in situ Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-Pr05 |
0.515 |
|
| 2016 |
Hanker AB, Estrada MV, Zhao J, Cheng F, Moore PD, Tyson D, Sanchez V, Rexer BN, Sanders M, Zhao Z, Stricker TP, Arteaga CL. Abstract 302: ECM/Integrin signaling promotes resistance to the combination of HER2 and PI3K inhibitors in HER2+, PIK3CA-mutant breast cancer Cancer Research. 76: 302-302. DOI: 10.1158/1538-7445.Am2016-302 |
0.612 |
|
| 2016 |
Sorace AG, Quarles CC, Whisenant JG, Hanker AB, McIntyre JO, Sanchez VM, Yankeelov TE. Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results Breast Cancer Research and Treatment. 155: 273-284. DOI: 10.1007/s10549-016-3680-8 |
0.423 |
|
| 2015 |
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nature Genetics. 47: 1212-9. PMID 26301495 DOI: 10.1038/Ng.3391 |
0.468 |
|
| 2015 |
Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, et al. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Molecular & Cellular Proteomics : McP. 14: 1959-76. PMID 25953087 DOI: 10.1074/Mcp.M115.049783 |
0.54 |
|
| 2015 |
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer Nature Genetics. DOI: 10.1038/ng.3391 |
0.509 |
|
| 2014 |
Hanker AB, Bulen B, Brewer MR, Young CD, Farrar KM, Cook RS, Stricker TP, Arteaga CL. Abstract 1822: HER2/PIK3CAH1047R transgenic tumors develop acquired resistance to triple therapy with trastuzumab, pertuzumab, and PI3K inhibitors via multiple mechanisms Cancer Research. 75: 1822-1822. DOI: 10.1158/1538-7445.Sabcs14-Pd5-8 |
0.546 |
|
| 2014 |
Young CD, Zimmerman LJ, Gatza ML, Morrison MM, Whitwell CA, Bhola NE, Hanker AB, Stricker T, Patel P, Brantley-Sieders DM, Perou CM, Park BH, Liebler DC, Cook RS, Arteaga CL. Abstract 970: Mass spectrometry analysis of PIK3CA mutant mammary epithelial cells identifies EGFR as a paracrine effector of PI3K in basal-like breast cancer Cancer Research. 74: 970-970. DOI: 10.1158/1538-7445.Am2014-970 |
0.583 |
|
| 2013 |
Hanker AB, Cook RS, Arteaga CL. Mouse models and anti-HER2 therapies. Oncotarget. 4: 1866-7. PMID 24272818 DOI: 10.18632/Oncotarget.1481 |
0.628 |
|
| 2013 |
Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 14372-7. PMID 23940356 DOI: 10.1073/Pnas.1303204110 |
0.615 |
|
| 2013 |
Young CD, Zimmerman LJ, Whitwell CA, Hanker AB, Stricker T, Brantley-Sieders DM, Park BH, Liebler DC, Cook RS, Arteaga CL. Abstract B015: Knock-in of PIK3CA mutations in MCF10A mammary epithelial cells modifies their proteomic profile to resemble basal-like breast cancer and stimulate EGFR-dependent cell proliferation Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-B015 |
0.565 |
|
| 2013 |
Hanker AB, Pfefferle A, Balko JM, Kuba MG, Young CD, Sanchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Abstract A007: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumor progression, enhances cancer stem cell features, and induces resistance to combinations of anti-HER2 therapies Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A007 |
0.628 |
|
| 2012 |
Hanker AB, Kuba MG, Sanchez V, Sutton CR, Pfefferle A, Balko JM, Perou CM, Cook RS, Arteaga CL. Abstract 4875: Human HER2 and PI3K H1047R cooperate to promote mammary tumorigenesis in vivo Cancer Research. 72: 4875-4875. DOI: 10.1158/1538-7445.Am2012-4875 |
0.332 |
|
| 2010 |
Hanker AB, Mitin N, Wilder RS, Henske EP, Tamanoi F, Cox AD, Der CJ. Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. Oncogene. 29: 380-91. PMID 19838215 DOI: 10.1038/Onc.2009.336 |
0.541 |
|
| 2010 |
Hanker AB, Chakrabarty A, Arteaga CL. Abstract B39: Identification of kinases that compensate for PI3K inhibition in breast cancer cells Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-B39 |
0.489 |
|
| 2010 |
Hanker AB, Der CJ. The roles of ras family small GTPases in breast cancer Handbook of Cell Signaling, 2/E. 3: 2763-2772. DOI: 10.1016/B978-0-12-374145-5.00322-3 |
0.569 |
|
| 2009 |
Hanker AB, Healy KD, Nichols J, Der CJ. Romidepsin inhibits Ras-dependent growth transformation of NIH 3T3 fibroblasts and RIE-1 epithelial cells independently of Ras signaling inhibition. Journal of Molecular Signaling. 4: 5. PMID 19682393 DOI: 10.1186/1750-2187-4-5 |
0.506 |
|
| 2008 |
Hanker AB, Morita S, Repasky GA, Ross DT, Seitz RS, Der CJ. Tools to study the function of the Ras-related, estrogen-regulated growth inhibitor in breast cancer. Methods in Enzymology. 439: 53-72. PMID 18374156 DOI: 10.1016/S0076-6879(07)00405-3 |
0.658 |
|
| 2008 |
Campbell P, Fiordalisi J, Hanker A, Boufaied N, Gourdeau H, Falardeau P, Cox A, Der C. 579 POSTER Biological and biochemical activity of TLN-4601 in pancreatic cancer European Journal of Cancer Supplements. 6: 181-182. DOI: 10.1016/S1359-6349(08)72513-8 |
0.475 |
|
| Show low-probability matches. |